Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lieping Chen
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial
Abstract Recurrent glioblastoma (rGBM) is a leading brain malignancy with few therapeutic options. Here we present the complete results of a phase 1 trial investigating the safety and efficacy of autologous B7-H3-targeting chimeric antigen receptor T (CAR-T) cell (TX103) therapy for the treatment of rGBM.
The liver-secreted protein FGL1 restrains a subset of innate-like B cell responses via the receptor TACI
|
Keywords FGL1 TACI BAFF APRIL LAG-3 BCMA B cell inhibitory autoimmunity lupus Get full text access Log in, subscribe or purchase for full access. References 1. Zhu, Y. ∙ Yao, S. ∙ Chen, L. Cell surface signaling molecules in the control of immune responses: a tide model Immunity. 2011; 34:466-478 2. Chen, L. ∙ Flies, D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition Nat. Rev. Immunol. 2013; 13:227-242 3.
By Tina Su, Jianwei He, Yuge Wang, Jiaoyan Huang, Baozhu Huang, Ala F. Nassar, Laure Willen, Mahya Eslami, ChunXiang Wu, Meiyi Huang, Jianping Zhang, Runxia Gu, Lan Ji, Ti Badri, Xuan Yang, Hyeon Jun Shin, Min-Jong Kang, Lokesh Sharma, Matthew Vesely, Yong Xiong Verified, Hongyu Zhao, Pascal Schneider, Jun Wang, Lieping Chen
|
Cell Press
Verified
Why has immune “checkpoint” therapy failed in most clinical trials?
The path forward Given these insights, the future of “checkpoint” therapy cannot rest on empirical combinations of immune modulators. Instead, it ought to be guided by a rigorous understanding of the tumor’s immunologic architecture, evolutionary dynamics, and context-specific vulnerabilities (figure 1).
PD-L1 and the dawn of modern cancer immunotherapy - Nature Medicine
Lieping Chen describes how his discoveries with PD-L1 yielded life-saving treatments for several cancers.
Study Uncovers At Least One Cause of Roadblocks to Cancer Immunotherapy
T cells — the body’s foot soldiers against invaders, ranging from everyday infections to cancers — are integral to many successful immunotherapies. Though a frustrating factor is that immunotherapies do not always work. More than half of human cancers, called “non-inflamed” or “cold” tumors, are not being effectively infiltrated by the cancer-fighting T cells . Essentially, the soldiers are excluded from the battlefield. Researchers want to know why.
Author Correction: Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability - Scientific Reports
Correction to: Scientific Reports https://doi.org/10.1038/s41598-017-06410-w, published online 20 July 2017 This Article contains an error in the Acknowledgements section. “We thank Beth Cadugan for editing the manuscript, Dr. Zhiyong Guo (The first affiliated hospital, Sun Yat-sen University) for generously sharing the Foxp3(GFP) knock-in mice, and Mr. Xiaobo Li for providing the technical support of cell sorting.
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Figure 3 TIME and anti-PD therapy missing target resistance. (a) Within the tumor microenvironment, T cells recognize and destroy cancer cells through various mechanisms, including IFN-γ, TNF-α, perforin, and granzyme B activities. (b) Over time, tumors develop immune escape mechanisms, such as increased expression of B7-H1 (PD-L1), in a process called adaptive immune resistance that results in a dysfunctional immune response.
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression
Abstract How tumor cells genetically lose antigenicity and evade immune checkpoints remains largely elusive. We report that tissue-specific expression of the human long noncoding RNA LINK-A in mouse mammary glands initiates metastatic mammary gland tumors, which phenotypically resemble human triple-negative breast cancer (TNBC).
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Four different TME groups with potential implications for mechanism and therapy have been identified according to B7-H1 (PD-L1) expression and the presence of TILs in tumor biopsies: I, B7-H1-negative tumors without TILs, considered immunological ignorant because immune cells do not accumulate at the tumor site, II, B7-H1-positive tumors with TILs, considered a paradigm of adaptive resistance of tumors mediated by the B7-H1/PD-1 pathway, III, B7-H1-negative tumors with TILs, considered a...
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Agarwala S.S. Glaspy J. O’Day S.J. Mitchell M. Gutheil J. Whitman E. Gonzalez R. Hersh E. Feun L. Belt R. et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J. Clin. Oncol. 2002; 20: 125-133 Ahmed N. Brawley V.S. Hegde M. Robertson C. Ghazi A. Gerken C. Liu E. Dakhova O. Ashoori A. Corder A. et al.
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
Highlights Recently, anti-PD therapy has taken center stage for the treatment of cancer, especially for solid tumors. While anti-PD therapy is highly effective in some patients (response), others do not respond (resistance). A proper understanding of the tumor microenvironment, both in terms of PD-L1/B7-H1 expression and of immune infiltration, is critical to separate true primary resistance from ‘target-missing’ resistance.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lieping
Contact Lieping, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack